Charles Theuer
CIK 1631338 · PRESIDENT AND CEO · last filed 2026-06-18
Charles Theuer is a PRESIDENT AND CEO who has filed 69 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for FDMT, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$694.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $512.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TCON price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4350 LA JOLLA VILLAGE DRIVE, SUITE 800
SAN DIEGO, CA 92122
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FDMT | Director | 41,684 | $12.29 | $512.3K | $0 | 7 | 2026-06-18 |
| Oncternal Therapeutics, Inc. (ONCT) Delisted | Director | 734 | $0.53 | $387 | $0 | 9 | 2024-06-24 |
| Tracon Pharmaceuticals, Inc. (TCON) Delisted | PRESIDENT AND CEO | 20,146 | $0.03 | $649 | $694.3K | 42 | 2024-03-13 |
Recent Filings
69 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2025-12-16 | FDMT | Exer (M) | +9,333 | $10.6K | EDGAR |
| 2025-06-20 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2024-06-24 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2024-03-13 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Grant (A) | +7,000 | $948 | EDGAR |
| 2023-06-30 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-25 | FDMT | Grant (A) | — | $0 | EDGAR |
| 2023-04-28 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Buy (P) | +50,999 | $37.9K | EDGAR |
| 2023-03-02 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Buy (P) | +5,000 | $7.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.